MedTrace Logo

Anti-Inflammatory Effects of Pioglitazone

NCT00722631 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2012-09-27

No results posted yet for this study

Summary

There is increasing evidence that inflammation plays a role in progression and destabilization of atherosclerotic plaque. FDG-PET can visualize activated metabolic activity of inflammatory cells. It is possible that FDG-PET can detect atherosclerotic plaque inflammation and that FDG-PET can monitor the effect of pioglitazone on plaque inflammation.

Conditions

Interventions

DRUG

Pioglitazone

Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.

DRUG

Glimepiride

Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.

Sponsors & Collaborators

  • Kurume University

    lead OTHER

Principal Investigators

  • Nobuhiro Tahara, MD, PhD · Kurume University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-04-30
Completion
2012-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722631 on ClinicalTrials.gov